Fig. 2: NSs displays reduced toxicity in MRC-5 cells.
From: Harnessing Rift Valley fever virus NSs gene for cancer gene therapy
A Bright field images of MRC-5 cells transfected with 2.5 ng of NSs mRNA, NSs mutant mRNA, or mock treatment were captured at 48 h post-transfection. Scale bar = 100 µm. B AlamarBlue cell viability assay was conducted on MRC-5 cells transfected with dose titrations ranging from 0.6 to 5 ng of NSs, NSs mutant, or GFP control mRNA at 48 h post-transfection. The treatments were made relative to the mock control set at 100%. Data presented as the mean ± S.D of triplicate treated cells. These data are one representative experiment which was performed two times.
